Journal article
Conversion From Sildenafil to Tadalafil: Results From the Sildenafil to Tadalafil in Pulmonary Arterial Hypertension (SITAR) Study
Robert P Frantz, Louise Durst, Charles D Burger, Ronald J Oudiz, Robert C Bourge, Veronica Franco, Aaron B Waxman, Susanne McDevitt, Susan Walker
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS | SAGE PUBLICATIONS INC | Published : 2014
Abstract
PURPOSE: Among phosphodiesterase type 5 inhibitors, tadalafil offers clinicians a once-daily alternative to 3 times daily sildenafil for the treatment of pulmonary arterial hypertension (PAH). This study assessed the safety and patient satisfaction with conversion from sildenafil to tadalafil. METHODS: In this multicenter, prospective, 6-month study, patients with PAH were instructed to take their last dose of sildenafil in the evening and initiate tadalafil 40 mg/d the next morning. Patients completed the Treatment Satisfaction Questionnaire for Medication at baseline and 30, 90, and 180 days after transition to assess PAH symptoms and patient satisfaction. Safety was assessed on the basis ..
View full abstractGrants
Funding Acknowledgements
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Support for this study was provided by United Therapeutics Corporation. Editorial assistance was provided under the direction of the authors by MedThink Communications with support from United Therapeutics Corporation. United Therapeutics Corporation provided support for data collection, data management, and statistical analysis. SM and SW are employees of United Therapeutics Corporation and as authors were involved in data interpretation and had the right to approve or disapprove publication of the finished manuscript. RF has served on advisory boards for United Therapeutics, without personal financial gain, aside from coverage of travel expenses, in keeping with the Mayo Clinic's conflict of interest policy for clinical investigators. He has received research funding for unrelated research projects and educational grants from United Therapeutics, without personal financial gain. LD serves on a steering committee for Medtronic, without personal financial gain, aside from coverage of travel expenses, in keeping with the Mayo Clinic's conflict of interest policy for study staff. CB has received research funding from Actelion Pharmaceuticals, Gilead Sciences, and United Therapeutics, without personal financial gain. RO has received consulting and/or steering committee honoraria from Actelion Pharmaceuticals, Bayer, Gilead Sciences, Lung Rx, Medtronic, Novartis Pharmaceuticals, Pfizer, and United Therapeutics. RO has received grant support for clinical trials from Actelion Pharmaceuticals, Bayer, Gilead Sciences, Lung Rx, Pfizer, and United Therapeutics. He has also received speaker fees from Gilead Sciences and United Therapeutics. RB has received research support from Pfizer, United Therapeutics, Gilead Sciences, Actelion Pharmaceuticals, Novartis Pharmaceuticals, Medtronic, GeNO, and Bayer. He serves as a consultant for United Therapeutics, Gilead Sciences, Actelion Pharmaceuticals, Novartis Pharmaceuticals, and Medtronic. He also has received compensation for participation in speakers bureaus for Gilead Sciences and United Therapeutics. VF has served on advisory boards for Gilead Sciences and Bayer and has received compensation for participation in Gilead Sciences' speakers bureau. AW is a consultant for United Therapeutics, Gilead Sciences, Pfizer, and Medtronic. He has also received research support from United Therapeutics, Gilead Sciences, Pfizer, and Medtronic, without personal financial gain. SM and SW are employees of United Therapeutics.